vs
Cyclerion Therapeutics, Inc.（CYCN）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Cyclerion Therapeutics, Inc.的季度营收约是Arcadia Biosciences, Inc.的1.1倍（$1.0M vs $901.0K），Cyclerion Therapeutics, Inc.净利率更高（-78.0% vs -148.3%，领先70.3%），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -43.2%）
Cyclerion Therapeutics是一家临床阶段生物制药公司，专注于发现、开发及商业化针对严重神经退行性疾病、罕见病与心代谢疾病的创新疗法，依托可溶性鸟苷酸环化酶调节技术，为全球存在未被满足医疗需求的患者提供治疗选择。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
CYCN vs RKDA — 直观对比
营收规模更大
CYCN
是对方的1.1倍
$901.0K
营收增速更快
RKDA
高出17.4%
-43.2%
净利率更高
CYCN
高出70.3%
-148.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0M | $901.0K |
| 净利润 | $-799.0K | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | -81.8% | -152.8% |
| 净利率 | -78.0% | -148.3% |
| 营收同比 | -43.2% | -25.8% |
| 净利润同比 | -250.8% | 67.1% |
| 每股收益（稀释后） | $-0.14 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CYCNRKDA
| Q4 25 | $1.0M | $901.0K | ||
| Q3 25 | $875.0K | $1.3M | ||
| Q2 25 | — | $1.5M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | $1.8M | $1.2M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | $0 | $1.3M | ||
| Q1 24 | $0 | $987.0K |
净利润CYCNRKDA
| Q4 25 | $-799.0K | $-1.3M | ||
| Q3 25 | $-976.0K | $856.0K | ||
| Q2 25 | — | $-4.5M | ||
| Q1 25 | — | $2.6M | ||
| Q4 24 | $530.0K | $-4.1M | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | $-1.3M | $1.1M | ||
| Q1 24 | $-1.5M | $-2.4M |
毛利率CYCNRKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率CYCNRKDA
| Q4 25 | -81.8% | -152.8% | ||
| Q3 25 | -115.0% | -88.5% | ||
| Q2 25 | — | -34.4% | ||
| Q1 25 | — | 44.2% | ||
| Q4 24 | 27.8% | -187.7% | ||
| Q3 24 | — | -114.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -160.9% |
净利率CYCNRKDA
| Q4 25 | -78.0% | -148.3% | ||
| Q3 25 | -111.5% | 65.7% | ||
| Q2 25 | — | -306.4% | ||
| Q1 25 | — | 216.6% | ||
| Q4 24 | 29.3% | -334.5% | ||
| Q3 24 | — | -104.9% | ||
| Q2 24 | — | 81.2% | ||
| Q1 24 | — | -245.5% |
每股收益（稀释后）CYCNRKDA
| Q4 25 | $-0.14 | $-0.97 | ||
| Q3 25 | $-0.30 | $0.62 | ||
| Q2 25 | — | $-3.26 | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | $0.23 | $-2.99 | ||
| Q3 24 | — | $-1.18 | ||
| Q2 24 | $-0.53 | $0.78 | ||
| Q1 24 | $-0.62 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.2M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.1M | $4.1M |
| 总资产 | $10.0M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CYCNRKDA
| Q4 25 | $3.2M | $4.6M | ||
| Q3 25 | $4.6M | $5.9M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | $3.2M | $4.2M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | $4.6M | $8.1M | ||
| Q1 24 | $5.7M | $8.5M |
股东权益CYCNRKDA
| Q4 25 | $9.1M | $4.1M | ||
| Q3 25 | $9.5M | $5.4M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $8.9M | ||
| Q4 24 | $8.8M | $6.2M | ||
| Q3 24 | — | $10.3M | ||
| Q2 24 | $8.8M | $11.7M | ||
| Q1 24 | $9.9M | $10.6M |
总资产CYCNRKDA
| Q4 25 | $10.0M | $6.5M | ||
| Q3 25 | $10.4M | $8.6M | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | $9.6M | $13.5M | ||
| Q3 24 | — | $15.2M | ||
| Q2 24 | $10.1M | $17.4M | ||
| Q1 24 | $11.4M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CYCNRKDA
| Q4 25 | $-1.6M | $-861.0K | ||
| Q3 25 | $-264.0K | $-257.0K | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $360.0K | $-2.2M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | $-1.1M | $-2.5M | ||
| Q1 24 | $-1.9M | $-3.2M |
自由现金流CYCNRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | — | $-3.2M |
自由现金流率CYCNRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度CYCNRKDA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率CYCNRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CYCN
| License Agreement | $1.0M | 98% |
| Other | $25.0K | 2% |
RKDA
暂无分部数据
